NCT07377435 — David Avigan cancer vaccine trial
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Registry record
| Registry ID | NCT07377435 ↗ |
|---|---|
| Lead sponsor | David Avigan |
| Collaborators | The V Foundation |
| Phase | Phase 1 |
| Status | Recruiting |
| Indication | Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma |
| Enrollment | 25 participants (target) |
| Start date | 2026-01-30 |
| Primary completion | 2028-03-01 (est.) |
| Last registry update | 8 May 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07377435), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
No modality, tumor or player hub covers this study yet. Browse the field map for the axes the daily brief does track.
Related trials
FAQ
What phase is NCT07377435?
NCT07377435 (DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM) is registered on ClinicalTrials.gov as Phase 1, sponsored by David Avigan.
Is NCT07377435 recruiting?
As of the 2026-05-08 registry update, NCT07377435 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07377435?
The lead sponsor is David Avigan. Collaborators: The V Foundation.
What condition does NCT07377435 study?
The registered conditions are Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma. Primary completion is listed as 2028-03-01 (estimated).
Are results available for NCT07377435?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07377435.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.